stride study semaglutide Data Deep Dive: The Latest Insights from STRIDE-PAD and SOUL What were the key findings

Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data

Asegrate de preguntarle sobre Ozempic en tu prxima visita

A.KhaireA

And the gap between approved and prescribed by the NHS is where one of the most consequential health stories of this decade is going to play out